Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NovoCure Limited    NVCR   JE00BYSS4X48


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure : to Host Virtual Research & Development Day

09/29/2020 | 07:31am EST

Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research

Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on Thursday, November 12, 2020, to highlight progress across its clinical and product development pipelines and to introduce areas of internal and external focus in its translational research. The event will include presentations from various leaders of Novocure’s research and development teams as well as from key opinion leaders from across the global scientific community who are conducting research on Tumor Treating Fields.

The event will be webcast live and can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. The webcast will be available for replay for at least 14 days following the event. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer and glioblastoma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

© Business Wire 2020
01/12NOVOCURE : Wedbush Adjusts NovoCure's Price Target to $159 From $110, Maintains ..
01/11NOVOCURE : Earnings Flash (NVCR) NOVOCURE Posts Q4 Revenue $144M
01/11NOVOCURE : Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues ..
2020NOVOCURE : to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conf..
2020INSIDER TRENDS : NovoCure Insider Sale Slowing 90-Day Buy Trend
2020NOVOCURE : Announces National Reimbursement in Switzerland for Optune® in Combin..
2020NovoCure Starts Enrollment in Phase 3 Trial of Optune as Glioblastoma Combina..
2020NOVOCURE : First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of ..
2020NOVOCURE : to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference
2020NOVOCURE : Announces 43 Presentations on Tumor Treating Fields at Society for Ne..
More news
Financials (USD)
Sales 2020 494 M - -
Net income 2020 26,5 M - -
Net cash 2020 160 M - -
P/E ratio 2020 678x
Yield 2020 -
Capitalization 17 019 M 17 019 M -
EV / Sales 2020 34,2x
EV / Sales 2021 28,7x
Nbr of Employees 782
Free-Float 85,2%
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 9
Average target price 148,38 $
Last Close Price 167,19 $
Spread / Highest target 34,6%
Spread / Average Target -11,3%
Spread / Lowest Target -47,4%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
William F. Doyle Executive Chairman
Wilhelmus Groenhuysen Chief Operating Officer
Ashley Cordova Chief Financial Officer, SVP-Investor Relations
Uri Weinberg Chief Science Officer
Sector and Competitors
1st jan.Capitalization (M$)
PENUMBRA, INC.46.25%9 293
ASAHI INTECC CO., LTD.-8.23%8 680
GETINGE AB3.36%6 502